在越南肝硬化门诊患者晚间小吃中蛋白质和BCAA之间的有效性比较:一项随机临床试验

相关实验视频

Updated: May 5, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Trang Thu Nguyen1, Linh Thuy Nguyen2, Shigeru Yamamoto3

  • 1Nutrition and Food Culture Research Center, Jumonji University, Saitama, Japan. trangnn27@gmail.com.

Journal of gastrointestinal and liver diseases : JGLD
|March 28, 2025
PubMed
概括

在肝硬化患者中,蛋白质零食显著改善了白蛋白水平和肝酶. 分链氨基酸 (BCAA) 零食的效果较低,这表明蛋白质是改善营养状况的更好的饮食选择.

更多相关视频

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice08:06

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

Published on: November 27, 2019

8.8K
The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model05:38

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model

Published on: April 12, 2024

236

相关概念视频

Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
728
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
658
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274